Matthew Sexton, MD
Family Medicine · Lexington, NENPI 1396271201
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $307 and has fallen 78.7% since, to $66 in 2025.
Across 61 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$174
- AbbVie$152
- AstraZeneca$145
- Novo Nordisk$138
- Johnson & Johnson$63
- Alkermes, Inc.$31
- plus $317 from 17 others
What the payments were for
- Food & beverage$1,020100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 12 | $174 |
| AbbVie | 10 | $152 |
| AstraZeneca | 4 | $145 |
| Novo Nordisk | 9 | $138 |
| Johnson & Johnson | 4 | $63 |
| Alkermes, Inc. | 2 | $31 |
| Astellas Pharma US Inc | 2 | $29 |
| Amgen | 2 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| Abbott | 1 | $23 |
| Abiomed | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Vyera Pharmaceuticals, LLC | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Sanofi | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Aurinia Pharma U.S., Inc. | 1 | $15 |
| Corcept Therapeutics | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Merck | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| GSK | 1 | $12 |
How this compares
$1,020 in reported general payments places this provider in the 60th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 42 | $23,955 |
| JardianceEmpagliflozin | 11 | $6,742 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $1,908 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 24 | $1,685 |
| Atorvastatin Calcium | 103 | $1,359 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $598 |
| Losartan Potassium | 52 | $570 |
| Tamsulosin Hcl | 33 | $487 |
| Lisinopril | 55 | $434 |
| Carvedilol | 34 | $415 |
| Levothyroxine Sodium | 34 | $404 |
| Potassium Chloride | 15 | $397 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 18 | $334 |
| Amlodipine Besylate | 56 | $318 |
| Metformin Hcl | 23 | $300 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Lexington
- Michael IsraelLincoln$375K
- Francisco DozonNorfolk$238K
- Randy KohlLincoln$67K
- James OmelGrand Island$67K
- Gerard StanleyOmaha$50K
- Jared KramerSt Paul$41K
- Randolph WaldmanHebron$27K
- Brian FinleyBellevue$20K
- William FitzgibbonsElkhorn$18K
- Michael BrennerSouth Sioux City$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.